Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Distillery Therapeutics

ADORA2A identified as a thrombosis target

May 6, 2019 7:25 PM UTC

INDICATION: Thrombosis

Cell culture and mouse studies suggest agonizing ADORA2A could help treat thrombosis. In primary human and mouse neutrophils treated with IgG from patients with antiphospholipid syndrome (APS), which is associated with thrombosis, a tool compound ADORA2A agonist decreased prothrombotic neutrophil extracellular trap (NET) levels compared with no treatment. In a mouse model of thrombosis and in the APS IgG-treated model, the ADORA2A agonist decreased thrombus incidence, weight and size. In another mouse model of thrombosis treated with APS patient IgG, the inhibitor decreased thrombus incidence, weight and size. Next steps could include testing other ADORA2A agonists in models of thrombosis...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

University of Michigan